RACE -0.03V 1.41TDG 2.37WDC 0.92MRVL -3.84NVDA -4.1CCEC.TO 0SDE.TO 0.585
Medtronic Inc (MDT)

NYSE:MDT

Medtronic Inc (MDT)

90.77
-0.98 (1.07%)
as of Sep 22, 2026, 8:00:00 pm Market Open.
183 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
BUY

Medtronic Inc(MDT)

Aug 13, 2009
Likes med-tech space. Space has historically traded at 20 PE’s and up. Growth is very good. Demographics are very positive. Currently out of favour because of fears of what the government will do to the industry. Trading at one of the lowest multiples in its 20-year history.
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$36.54

Stock price when the opinion was issued

$90.23

As of Sep 23, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Medtronic Inc(MDT)

Apr 21, 2009
Model $42.48.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$30.56

Stock price when the opinion was issued

$90.23

As of Sep 23, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Medtronic Inc(MDT)

Feb 24, 2009
He has a model price of $41.29 giving it a 21% positive differential. Just reported greater earnings. 2% yield.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$34.52

Stock price when the opinion was issued

$90.23

As of Sep 23, 2026. Market Open.

biotechnologypharmaceutical
BUY

Medtronic Inc(MDT)

Sep 08, 2008
Likes medical devices sector. Of all the sectors, medical equipment is one of the tops. Regardless of what is going on in the economies , medical devices will continue to sell. He owns Zoll Medical (ZOLL-Q) instead, which has more growth potential. Thinks there is more upside potential in the small/mid-cap size names.
Photo of Matthew McCallMatthew McCall
No
Unlock Rating
$54.24

Stock price when the opinion was issued

$90.23

As of Sep 23, 2026. Market Open.

biotechnologypharmaceutical
BUY

Medtronic Inc(MDT)

Mar 22, 2007
PE of about 20 and anticipated growth rate of about 14%. Have a lot of intellectual property. Reasonably attractive.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$49.79

Stock price when the opinion was issued

$90.23

As of Sep 23, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Medtronic Inc(MDT)

Jan 17, 2007
His model price is $41.45 so it is a negative 23%-24% differential. This is one of those stocks that is perpetually overvalued.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$54.30

Stock price when the opinion was issued

$90.23

As of Sep 23, 2026. Market Open.

biotechnologypharmaceutical
BUY

Medtronic Inc(MDT)

Sep 27, 2006
Likes a lot of the big US healthcare stocks. Valuation is reasonable.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$47.25

Stock price when the opinion was issued

$90.23

As of Sep 23, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Medtronic Inc(MDT)

Jul 11, 2006
On his watch list as a possible investment. Valuation has been hurt but the fundamentals have not changed much. The long-term outlook for their products is very good.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$47.98

Stock price when the opinion was issued

$90.23

As of Sep 23, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Medtronic Inc(MDT)

Jul 30, 2004
A high quality, growth company. Good price. The leading medical technology company in the world.
Photo of Daniel Boone IIIDaniel Boone III
Owned
Unlock Rating
$49.67

Stock price when the opinion was issued

$90.23

As of Sep 23, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Medtronic Inc(MDT)

Jul 02, 2004
Solid earnings. Feels their new stent will be successful next year.
Photo of Nicholas SargenNicholas SargenUnlock Rating
$49.62

Stock price when the opinion was issued

$90.23

As of Sep 23, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Medtronic Inc(MDT)

Feb 10, 2004
Interesting company. Market is very strong for their products. Stock isn't cheap. Has been growing slowely
Photo of Brad WillockBrad Willock
Owned
Unlock Rating
$46.70

Stock price when the opinion was issued

$90.23

As of Sep 23, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Medtronic Inc(MDT)

Sep 08, 2003
Valuation is a little bit ahead of the stock. Very good management.
Photo of Paul O'NeilPaul O'NeilUnlock Rating
$48.45

Stock price when the opinion was issued

$90.23

As of Sep 23, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Medtronic Inc(MDT)

Jul 30, 2002
Competition. Too expensive at 30 X earnings.
Photo of David DriscollDavid DriscollUnlock Rating
$39.47

Stock price when the opinion was issued

$90.23

As of Sep 23, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Medtronic Inc(MDT)

Jul 17, 2002
Great company. Buy in the mid to low $20's.
Photo of Paul O'NeilPaul O'NeilUnlock Rating
$39.38

Stock price when the opinion was issued

$90.23

As of Sep 23, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Medtronic Inc(MDT)

Mar 04, 2002
Good company. Not a cheap stock. A cash machine.
Photo of David BaskinDavid BaskinUnlock Rating
$45.14

Stock price when the opinion was issued

$90.23

As of Sep 23, 2026. Market Open.

biotechnologypharmaceutical
Showing 106 to 120 of 127 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

RY.TO -3.41$283.76
META 19.075$755.67
SYK -1.305$273.785
LYV 0.015$169.855
DPZ -5.205$291.91
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

RACE -0.03$413.29
V 1.41$363.45
TDG 2.37$1114.79
WDC 0.92$465.52
MRVL -3.84$258.52

Popular Articles

Latest Sell Signals

CPX.TO 0.06$62.36
CPRT -0.22$28.575
UBER -0.43$69.46
DOL.TO -1.58$179.1
BLK -0.26$1066.4

Most Recent Experts

Ernest Wong, Head of Research, Baskin Wealth Management

Ernest Wong, Head of Research, Baskin Wealth Management

Baskin Wealth Management

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jim Lebenthal

Jim Lebenthal

Cerity Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like